EDAP's lithotripter approved in Korea
This article was originally published in Clinica
Executive Summary
Sonolith i-move, a lithotripter developed by therapeutic ultrasound specialist EDAP TMS (Lyon, France), has been approved for sale by the South Korean Food and Drug Administration (KFDA). Lithotripters break up kidney or other stones using sonic shock waves. The Sonolith i-move has an infrared stereo-vision system for real-time, three-dimensional ultrasound-free localisation of urinary stones. South Korea is the second largest market in Asia for lithotripsy devices, after Japan. The device is awaiting approval in the US and Japan.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.